CliffBio
biologic

Exdensur

depemokimab-ulaa

Loss of exclusivityDecember 2037projected — 12-year biologic exclusivity estimate
CompanyGlaxoSmithKline →View the full company profile on CliffBio

Drug detail

Brand nameExdensur
Active ingredientdepemokimab-ulaa
Strength100MG/ML
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalDecember 2025
Marketing statusRx

More from GlaxoSmithKline

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Exdensur patent cliff — loss of exclusivity December 2037 | CliffBio